

## **INVESTOR WEBINAR – PIVALATE POSITIVE PHASE 2 DATA**

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to invite shareholders, investors and other interested parties to a webinar with its Executive Chairman Paul Hopper and CEO and Managing Director Riccardo Canevari.

The webinar will discuss today’s announcement regarding positive Phase 2a data from Imperial College London’s F-18 Pivalate technology, for which Radiopharm acquired an exclusive worldwide licence.

The webinar will be held today, Tuesday 18 October 2022 at 3:30pm AEDT.

For the Q&A session, investors are invited to send questions prior to the webinar to [matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au).

Register for the webinar at the link below:

[https://us02web.zoom.us/webinar/register/WN\\_oxgnZZfoQiWHzko-VaAJvA](https://us02web.zoom.us/webinar/register/WN_oxgnZZfoQiWHzko-VaAJvA)

After registering, you will receive a confirmation email containing information about joining the webinar as well as dial-in details for those that would prefer to join by phone. A recording will be available at the above link shortly after the conclusion of the live session.

**Authorised on behalf of the Radiopharm Theranostics board of directors by Executive Chairman Paul Hopper.**

**For more information:**

Riccardo Canevari  
CEO & Managing Director  
P: +1 862 309 0293  
E: [rc@radiopharmtheranostics.com](mailto:rc@radiopharmtheranostics.com)

Paul Hopper  
Executive Chairman  
P: +61 406 671 515  
E: [paulhopper@lifescienceportfolio.com](mailto:paulhopper@lifescienceportfolio.com)

Media

Matt Wright  
NWR Communications  
P: +61 451 896 420  
E: [matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

**Follow Radiopharm Theranostics:**

Website – <https://radiopharmtheranostics.com/>

Twitter – <https://twitter.com/TeamRadiopharm>

Linked In – <https://www.linkedin.com/company/radiopharm-theranostics/>